Another alternative explanation for why cetuximab did not induce CD16a shedding by these tumor-infiltrating NK cells from patients is that an addition of recombinant interleukin 15 protein may be needed to better support NK cell survival and functions in tumor explants, but in our study we did not add interleukin 15 to the tumor explants. Here, FCGR3A is linked to neoplasm.